
A study on the real-world efficacy and safety of anlotinib-containing regimens for non-small cell lung cancer (NSCLC) treatment reveals promising results. Involving 240 advanced NSCLC patients, the research found an overall median progression-free survival (PFS) of 8.5 months. Notably, anlotinib combined with immunotherapy achieved a significantly longer PFS of 10.5 months compared to 6.5 months with anlotinib monotherapy. Adverse reactions were generally mild, with hypertension being the most common. The study suggests anlotinib's effectiveness and tolerability in advanced NSCLC patients and the potential of immunotherapy combination for improved outcomes.
Like
Save
Share